Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00022438 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00025012 | Isotretinoin in Preventing Skin Cancer | completed | N/A | — | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH | 1 | Jun 19, 2013 |
| clinicaltrials |
| NCT00054535 | Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00072085 | Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00072124 | Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma | completed | Phase 3 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00079144 | Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00671918 | Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma | completed | Phase 3 | 186 | Navidea BiopharmaceuticalsINDUSTRY | 2 | Jun 17, 2013 | clinicaltrials |
| NCT01106040 | Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes | completed | Phase 3 | 163 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Jun 17, 2013 | clinicaltrials |
| NCT00313235 | Combined Modality Treatment for Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 41 | Baylor Research InstituteOTHER | 1 | Jun 13, 2013 | clinicaltrials |
| NCT01245556 | Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma | completed | Phase 1 | 8 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 12, 2013 | clinicaltrials |
| NCT00004016 | Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors | completed | Phase 1 | — | University of RochesterOTHER | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00026143 | Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00027742 | Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00060125 | Tipifarnib in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00513604 | Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | completed | Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Jun 3, 2013 | clinicaltrials |
| NCT00005943 | Gene Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 | — | University of Colorado, DenverOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00005968 | Irofulven in Treating Patients With Stage IV Melanoma | completed | Phase 2 | — | University of Colorado, DenverOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT00346008 | Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members | completed | — | 2,500 | Iceland Genomics CorporationINDUSTRY | 1 | May 30, 2013 | clinicaltrials |
| NCT00095953 | SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | May 17, 2013 | clinicaltrials |
| NCT00112476 | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00217542 | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT01253759 | Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma | completed | — | 46 | New England Retina AssociatesOTHER | 1 | May 3, 2013 | clinicaltrials |
| NCT00006368 | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00112216 | Immunotherapy of Melanoma Patients | completed | Phase 1 | 9 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT00112229 | Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients | completed | Phase 1 | 29 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 22, 2013 | clinicaltrials |
| NCT00004184 | Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 50 | University of Alabama at BirminghamOTHER | 0 | Apr 12, 2013 | clinicaltrials |
| NCT00085423 | Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00568048 | Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 62 | Swiss Cancer InstituteOTHER | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00238329 | PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 2 | 32 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 8, 2013 | clinicaltrials |
| NCT00004022 | Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2013 | clinicaltrials |
| NCT00091143 | Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | completed | Phase 1 | 20 | Providence Cancer Center, Earle A. Chiles Research InstituteOTHER | 1 | Apr 4, 2013 | clinicaltrials |
| NCT00014092 | Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated With Surgery | completed | Phase 2 | — | Saint Francis HospitalOTHER | 1 | Mar 26, 2013 | clinicaltrials |
| NCT00003229 | Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal | completed | Phase 1 / Phase 2 | — | Duke UniversityOTHER | 1 | Mar 25, 2013 | clinicaltrials |
| NCT00004244 | Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00104845 | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | completed | Phase 1 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 12, 2013 | clinicaltrials |
| NCT00288041 | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2013 | clinicaltrials |
| NCT00512889 | Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma | completed | Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 1, 2013 | clinicaltrials |
| NCT00003665 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00002754 | Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors | completed | Phase 1 | 6 | Duke UniversityOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00004148 | Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00005961 | O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00017316 | Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00003556 | Vaccine Therapy in Treating Patients With Melanoma | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2013 | clinicaltrials |
| NCT00030615 | Decitabine in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00006243 | Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma | completed | N/A | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00036764 | BMS-247550 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00072345 | Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00072163 | Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jun 19, 2013source: clinicaltrials